Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic

Yeqian Zhao1,2,3, Weijie Cao4, Jimin Shi1,2,3

  • 1Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, 311100, China.

Blood Cancer Journal
|June 26, 2026
PubMed
Abstract

No abstract available in PubMed .